Profile cover photo
Profile photo
Nilogen Oncosystems
4 followers
4 followers
About
Posts

Post has attachment
Phase I of Compugen's investigational immunotherapy inhibitor ILDR2 began! Do you have a drug whose potential has been discovered using computational discovery? Do you want to enter a pre-clincal platform to evaluate its effectiveness and mechanism? Nilogen's 3D-Ex is for you!
Add a comment...

Post has attachment
Second generation of SERDs deliver a one-two punch, by inhibiting growth signals and blocking estrogen binding leading to the inhibition of the growth of of breast cancer cells. Have novel therapy to test in a pre-clinical platform? Then Nilogen's 3D-Ex platform is for you!
Add a comment...

Post has attachment
New EFIRM technology enables the detection of early-stage lung cancer when a surgical cure is still possible. Together with early detection, early treatment may be key and Nilogen Oncosystems' platform can help at an early stage of resection. Get in touch to find out how!
Add a comment...

Post has attachment
MedImmune’s MEDI0457, can safely be used in combination with anti-PD-1 therapy in patients with HPV-associated head and neck cancer! Is there a combination therapy you'd like to test in a proof-of-concept, pre-clinical setting? Nilogen's fresh tissue 3D Ex platform is for you!
Add a comment...

Post has attachment
Are you interested in a biomarker that could lead to a better outcome of your potential immunotherapy drug of interest? Nilogen Oncocystems' pre-clinical 3D-Ex platform could help you discover such biomarkers through tumor mutation burden and DNA analysis. Ask us how!
Add a comment...

Post has attachment
Do you have an IO drug of interest that you need to first test in a pre-clincal platform prior to a clinical trial survival study? Nilogen Oncosystems' 3D-Ex platform helps decipher the mechanism of action of your IO drug prior the clinic to assure its effectiveness. Ask us how!
Add a comment...

Post has attachment
Congratulations Dr. Allison and Dr. Honjo for winning the Nobel prize! Together, they discovered how to fight cancer using the body's immune system and opened up the whole new world to fighting cancer-immunotherapy!
Add a comment...

Post has attachment
Urothelial cancer's stromal cells are key in resistance to immunotherapy. Nilogen Oncosystem's 3D-Ex vivo fresh tumor model provides an intact tumor microenvironment to assess all essential cells' role in shaping the resistance of different tumor types to key IO drugs available.
Add a comment...

Post has attachment
A new study suggests that the cytokine CXCL12 could be useful as a prognostic biomarker in patients with lung NETs. Are you interested in finding a biomarker that can lead to better patient qualifications for your IO drug if interest? Nilogen's pre-clincal platform can help!
Add a comment...

Post has attachment
New study shows that hyperprogressive disease occurred more commonly among patients with pre-treated NSCLC receiving PD-1/PD-L1 inhibitors than in patients treated with chemotherapy. Timing and type of IO treatment is crucial for all patients.
Add a comment...
Wait while more posts are being loaded